A new PNH agent must beat iptacopan's oral bar in the EVH-anaemia cohort that anti-C5 blockade cannot resolve, within iptacopan's own pricing ceiling.

Ravulizumab and eculizumab together cover roughly 80% of the approximately 3,500 US PNH patients on complement-inhibitor therapy, with switching inertia high once patients are haemolysis-controlled and clinically stable on IV anti-C5. The clinical gap that keeps the market open: 25-35% of C5-inhibitor patients, an estimated 800-1,200 US patients, have persistent anaemia from extravascular haemolysis, a mechanism proximal to C5 that anti-C5 blockade does not address. Iptacopan (Fabhalta), approved November 2023, already claimed the first-mover oral and proximal-complement slot against this exact cohort, reporting an 82% haemoglobin responder rate and building roughly 10% US share within six months of launch.

For a pre-launch entrant, iptacopan's evidence and pricing now define the bar, not the anti-C5 incumbents. The addressable population is narrower than all PNH: the EVH-dominant, transfusion-requiring segment, an estimated 600-900 US patients transfusing at least once a year despite C5 inhibition, is the FDA-recognised, commercially defensible target that iptacopan's own trial data did not fully close out. A second consideration is diagnosis: 500-700 new US PNH patients are identified annually, with a 1-2 year diagnostic delay and an estimated 200-400 patients a year going undertreated at non-PNH-centre hospitals, an addressable but currently underserved volume.

Iptacopan's own trial data did not fully close out the EVH-dominant segment.

Five questions this report answers:

Q1 - What must a new PNH agent prove to overcome switching inertia and clear iptacopan's oral bar?

Q2 - How large is the US EVH-dominant PNH cohort, and how should it be tracked?

Q3 - What PA criteria and value benchmarks are payers setting for oral PNH agents now?

Q4 - What deliverable formats come with a commissioned US PNH launch readiness assessment?

Q5 - How large is the unmet-need PNH cohort a pre-launch asset should target?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PNH #RareDisease #USMarketAccess #LaunchReadiness #Hematology

Live report page:  https://axlrx.ai/pnh/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-     hello@axlrx.ai

Web-     https://axlrx.ai/